AZN icon

AstraZeneca

75.00 USD
+1.26
1.71%
At close Jun 12, 4:00 PM EDT
After hours
74.50
-0.50
0.67%
1 day
1.71%
5 days
3.56%
1 month
8.77%
3 months
-0.75%
6 months
12.04%
Year to date
13.84%
1 year
-6.33%
5 years
45.72%
10 years
128.31%
 

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Employees: 94,300

0
Funds holding %
of 7,295 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

191% more call options, than puts

Call options by funds: $855M | Put options by funds: $294M

62% more funds holding in top 10

Funds holding in top 10: 13 [Q4 2024] → 21 (+8) [Q1 2025]

58% more first-time investments, than exits

New positions opened: 147 | Existing positions closed: 93

40% more repeat investments, than reductions

Existing positions increased: 516 | Existing positions reduced: 368

9% more capital invested

Capital invested by funds: $34.1B [Q4 2024] → $37.3B (+$3.21B) [Q1 2025]

2% more funds holding

Funds holding: 1,202 [Q4 2024] → 1,222 (+20) [Q1 2025]

0.78% less ownership

Funds ownership: 33.12% [Q4 2024] → 32.35% (-0.78%) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for AZN.

Financial journalist opinion

Based on 24 articles about AZN published over the past 30 days

Positive
Proactive Investors
13 hours ago
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes
UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus is on two high-profile drug candidates with contrasting outlooks.
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes
Positive
Zacks Investment Research
6 days ago
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Neutral
Fox Business
1 week ago
AstraZeneca CEO: We totally agree with President Trump on this
AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' #foxbusiness #health #trump #maha
AstraZeneca CEO: We totally agree with President Trump on this
Positive
CNBC
1 week ago
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Neutral
Zacks Investment Research
1 week ago
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Positive
CNBC Television
1 week ago
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Positive
CNBC Television
1 week ago
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, and more.
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
Neutral
Investors Business Daily
1 week ago
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Positive
CNBC Television
1 week ago
Experimental AstraZeneca pill helps cut risk of breast cancer progression
CNBC's Joe Kernen reports on the latest news.
Experimental AstraZeneca pill helps cut risk of breast cancer progression
Positive
Skynews
1 week ago
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found.
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
Charts implemented using Lightweight Charts™